Drug profile · INN
ambenonium chloride
MYTELASE
ambenonium chloride (MYTELASE) is a acetylcholinesterase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — ambenonium chloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ambenonium chloride (MYTELASE) is a acetylcholinesterase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Acetylcholinesterase inhibitor
Primary target: Acetylcholinesterase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ambenonium chloride?
ambenonium chloride (MYTELASE) is a acetylcholinesterase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ambenonium chloride?
MYTELASE is a marketed brand name for ambenonium chloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ambenonium chloride?
ambenonium chloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.